Hsu, Fan-Chi Hudson, Chad Wilson, Elisabeth R Pardo, Laura M Singleton, Timothy P Xu, Dongbin Zehentner, Barbara K Hitzler, Johann Berman, Jason Wells, Denise A
...
Published in
Cytometry. Part B, Clinical cytometry
Detection of measurable residual disease detection (MRD) by flow cytometry after the first course of chemotherapy is a standard measure of early response in patients with acute myeloid leukemia (AML). Myeloid leukemia associated with Down Syndrome (ML-DS) is a distinct form of AML. Differences in steady-state and regenerating hematopoiesis between ...
Zhou, Ting Karrs, Jeremiah Ho, Truc Doverte, Alyssa Kochenderfer, James N Shah, Nirali N Yuan, Constance M Wang, Hao-Wei
Published in
Cytometry. Part B, Clinical cytometry
Multiparametric flow cytometry (MFC) has become a powerful tool in minimal residual disease (MRD) detection in B-lymphoblastic leukemia/lymphoma (B-ALL). In the setting of targeted immunotherapy, B-ALL MRD detection often relies on alterative gating strategies, such as the utilization of CD22 and CD24. It is important to depict the full diversity o...
Jurado, Rebeca Huguet, Maria Xicoy, Blanca Cabezon, Marta Jimenez-Ponce, Ari Quintela, David De La Fuente, Cristina Raya, Minerva Vinets, Esther Junca, Jordi
...
Published in
Cytometry. Part B, Clinical cytometry
The presence of >94% classical monocytes (MO1, CD14++/CD16-) in peripheral blood (PB) has an excellent performance for the diagnosis of chronic myelomonocytic leukemia (CMML). However, the monocyte gating strategy is not well defined. The objective of the study was to compare monocyte gating strategies and propose an optimal one. This is a prospect...
Gao, Qi Liu, Ying Aypar, Umut Baik, Jeeyeon Londono, Dory Sun, Xiaotian Zhang, Jingping Zhang, Yanming Roshal, Mikhail
Published in
Cytometry. Part B, Clinical cytometry
Measurement of minimal/measurable residual disease (MRD) in B-lymphoblastic leukemia/lymphoma (B-ALL) has become a routine clinical evaluation tool and remains the strongest predictor of treatment outcome. In recent years, new targeted anti-CD19 and anti-CD22 antibody-based and cellular therapies have revolutionized the treatment of the high-risk B...
Ramalingam, Thulasi Raman Uthayasuriyan, Ragavi Prabhakar, Vikram Vaidhyanathan, Lakshman
Published in
Cytometry. Part B, Clinical cytometry
McMillan, Annabel Tran, Thien-An Galas-Filipowicz, Daria Camilleri, Marquita Lecat, Catherine Ainley, Louise Guo, Yanping Yong, Kwee Sive, Jonathan
Published in
Cytometry. Part B, Clinical cytometry
Achieving minimal residual disease (MRD) negativity following treatment for multiple myeloma (MM) is associated with improved progression free and overall survival. In the UK, MRD assessments in MM are not incorporated into routine clinical use outside trials. Widely used in other haematological malignancies, there is a role for widening the availa...
Huang, Sara L Fennell, Thomas Chen, Xia Huang, James Z
Published in
Cytometry. Part B, Clinical cytometry
Surface immunoglobulin (sIg) light chains are not always detected on mature B cells. This may present as a challenge for clonality determination in clinical flow cytometry. To explore the mechanism and diagnostic significance of sIg negative mature B cells, we retrospectively studied 14 cases of sIg negative reactive B-cell lymphocytosis and 89 cas...
Chen, Xueyan Gao, Qi Roshal, Mikhail Cherian, Sindhu
Published in
Cytometry. Part B, Clinical cytometry
Minimal/measurable residual disease (MRD) is the most important independent prognostic factor for patients with B-lymphoblastic leukemia (B-LL). MRD post therapy has been incorporated into risk stratification and clinical management, resulting in substantially improved outcomes in pediatric and adult patients. Currently, MRD in B-ALL is most common...
Chan, Alexander Kumar, Priyadarshini Gao, Qi Baik, Jeeyeon Sigler, Allison Londono, Dory Liu, Ying Arcila, Maria E Dogan, Ahmet Zhang, Yanming
...
Published in
Cytometry. Part B, Clinical cytometry
Lineage infidelity is characteristic of mixed phenotype acute leukemia and is also seen in blast phase of chronic myeloid leukemia (CML), myeloid/lymphoid neoplasia with eosinophilia and gene rearrangements, and subtypes of acute myeloid leukemia. Driver genetic events often occur in multipotent progenitor cells in myeloid neoplasms, suggesting tha...
Gao, Qi Chen, Xueyan Cherian, Sindhu Roshal, Mikhail
Published in
Cytometry. Part B, Clinical cytometry
Flow cytometry has been indispensable in diagnosing B cell lymphoma and plasma cell neoplasms. The advances in novel multicolor flow cytometry have also made this technology a robust tool for monitoring minimal/measurable residual disease in chronic lymphocytic leukemia and multiple myeloma. However, challenges using conventional gating strategies ...
